1[1]World Health Organization,WHO Collaborating Centre for Drug Monitoring.The importance of pharmacovigilance.Safety monitoring of medicinal products.2002.
2[2]Begand B.Pharmacovigilance in France:a decentralized approach.In:Strom BL,Velo G,eds.Drug epidemiology and post-marketing surveillance.New York:Plenum Press,1992,39-42.
3[3]Begand B.Glossary.In:ARME-P.eds.Methodological approaches in pharmacoepidemiology.Amsterdam:Elsevier Science Publishers B.V.,1993,157-171.
4[4]Rawlins MD,Fracchia GN,Rodriguez-Farré E.EURO-ADR:Pharmacovigilance and research.A European perspective.Pharmacoepidemiol Drug Saf,1992,1:261-268.
5[5]Meyboom RHB,EgbertS ACG,Gribnau FWJ.et al.Pharmacovigilance in Perspective.Drug saf,1999,21:429-447.
6[6]Mehta U,Milstien JB,Duclos P,et al.Developing a national system for dealing with adverse events following immunization.Bulletin of the World Health Organization,2000,78(2):170-177.
7[7]Hartigan-Go K.Pharmacovigilance and the pursuit of rational drug use.The Philippines Experience.Uppsala Reports,14,April 2001Supplement.
8[8]Van Grootheest K.The dawn of pharmacovigilance:an historical perspective.Intemat J pharmaceutical Medicine,2003,17:195-200.
9[9]Rawlins MD.Spontaneous reporting of adverse drug reactions.Br J Clin Pharmacol,1988,26:1-11.
10[10]Meyboom RHB,Gribnau FWJ,Hekster YA,et al.Characteristics of topics in pharmacovigilance in The Netherlands.Clin Drug Invest,1996,4:207-219.
